SOTIO receives EMA approval

SOTIO receives European Medicines Agency approval to initiate Phase III VIABLE Clinical Trial of DCVAC/PCa, an active cellular immunotherapy drug targeted for prostate cancer patients. Lead Candidate from SOTIO’s DCVAC program.


SOTIO a.s. appoints Chiltern International

SOTIO a.s. has selected Chiltern International Limited to be the Contract Research Organization (CRO) that carries out the European part of its phase III global clinical trial entitled VIABLE, which will include 1,170 prostate cancer patients from Europe and the U.S.


SOTIO, a part of PPF Group

SOTIO has become a part of the PPF Group’s portfolio – one of the largest investment and finance groups in Central and Eastern Europe. The administrative process of the transfer of the equity interest was completed towards the end of 2012.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies